Drug Patents owned by Gilead Sciences

1. Drug name - ATRIPLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716264 GILEAD SCIENCES Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

US9744181 GILEAD SCIENCES Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

US8592397 GILEAD SCIENCES Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

US9457036 GILEAD SCIENCES Compositions and methods for combination antiviral therapy Jan, 2024

(1 year, 3 months from now)

US9545414 GILEAD SCIENCES Unitary pharmaceutical dosage form Jun, 2026

(3 years from now)

US9018192 GILEAD SCIENCES Unitary pharmaceutical dosage form Jun, 2026

(3 years from now)

US8598185 GILEAD SCIENCES Unitary pharmaceutical dosage form Apr, 2029

(6 years from now)

Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Treatment: Treatment of hiv infection; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; treatment of hiv-1 infection in adults; Treatment of hiv-1 infection in adults; treatment of hiv-1 infection in pediatric patients 12 years of age and older

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
600MG;200MG;300MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.